Candel Therapeutics (NASDAQ:CADL – Get Free Report) and Protalix BioTherapeutics (NYSE:PLX – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends and institutional ownership.
Institutional and Insider Ownership
13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 41.6% of Candel Therapeutics shares are held by company insiders. Comparatively, 5.0% of Protalix BioTherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Candel Therapeutics and Protalix BioTherapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Candel Therapeutics | $120,000.00 | 1,629.14 | -$37.94 million | ($1.28) | -5.13 |
| Protalix BioTherapeutics | $38.05 million | 2.04 | $8.31 million | $0.04 | 26.50 |
Profitability
This table compares Candel Therapeutics and Protalix BioTherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Candel Therapeutics | N/A | -629.29% | -134.23% |
| Protalix BioTherapeutics | -38.62% | -45.15% | -16.63% |
Volatility and Risk
Candel Therapeutics has a beta of -0.94, indicating that its stock price is 194% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations for Candel Therapeutics and Protalix BioTherapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Candel Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
| Protalix BioTherapeutics | 0 | 0 | 1 | 0 | 3.00 |
Candel Therapeutics presently has a consensus target price of $11.00, suggesting a potential upside of 67.43%. Protalix BioTherapeutics has a consensus target price of $10.00, suggesting a potential upside of 843.40%. Given Protalix BioTherapeutics’ higher probable upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Candel Therapeutics.
Summary
Protalix BioTherapeutics beats Candel Therapeutics on 9 of the 12 factors compared between the two stocks.
About Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
About Protalix BioTherapeutics
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
